The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, I speak with Dr. Timothy Burns, Professor of Medicine at The Ohio State University, about KRAS inhibitors within the evolving spectrum of systemic therapies for Non-Small Cell Lung Cancer (NSCLC). We discuss KRAS mutations, treatment resistance, immunotherapy combinations, biomarker testing, brain metastases, and his journey into lung cancer research. Listen now on all major platforms! “KRAS mutations represent a major therapeutic target across cancers, creating opportunities for increasingly selective inhibitors designed around specific molecular alterations.” Meet the guest: Dr. Timothy Burns https://www.linkedin.com/in/timothy-burns-61b6708/ is Professor of Medicine at The Ohio State University Comprehensive Cancer Center. With more than 89 publications and NCI R01 funding, his research advances targeted therapies for oncogene-driven NSCLC and brain metastases. He has led multiple clinical trials, including early-phase studies contributing to the approval of the KRAS G12C inhibitor sotorasib. Listen to Dr. Timothy Burns on The Oncology Insights Podcast, available on all major platforms. Liked this one? Don’t stop now. Here’s what we think you’ll love: https://www.wisenetix.com/blog?tag=the+oncology+insights+podcast What you will learn: (00:00) Highlight (01:01) Introduction (06:41) Targeting KRAS mutations (10:41) Resistance mechanisms (14:15) Therapy combinations (20:01) Brain metastases (28:04) Future KRAS strategies (35:28) Closing thoughts The Oncology Insights Podcast is trusted and supported by innovative companies like: - WiseVAs (https://www.wisevas.io/) - Elevate (https://elevateagents.ai/) - Zentrix Insights (https://zentrixinsights.com/) - ZentrixOS (https://zentrixos.com/) 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://oncologyinsightspodcast.com/ LinkedIn: https://www.linkedin.com/showcase/106601380/admin/dashboard/ Instagram: https://www.instagram.com/oncologyinsightspodcast/ Facebook: https://www.facebook.com/profile.php?id=61573169439464 TikTok: https://www.tiktok.com/@oncology.insights?lang=pt-BR

In this episode of The Oncology Insights Podcast, I speak with Dr. Michael Hofman, a nuclear medicine physician and professor at Peter MacCallum Cancer Centre, about the evolution of theranostics and targeted radiopharmaceutical therapy. We examine radioactive iodine, PSMA PET imaging, lutetium 177 therapy, prostate cancer applications, and opportunities to expand these approaches across oncology. Listen now on all major platforms! “Lutetium 177 delivers targeted radiation over a short distance after binding to tumor cells, helping limit radiation exposure across most normal tissues.” Meet the guest: Dr. Michael Hofman https://www.linkedin.com/in/drhofman/ is a nuclear medicine physician and professor at Peter MacCallum Cancer Centre whose research focuses on PSMA PET imaging, radioligand therapy, and prostate cancer. He has led multicenter clinical trials supporting advances in targeted cancer imaging and treatment, published more than 300 papers, and secured substantial research funding. Listen to Dr. Michael Hofman on The Oncology Insights Podcast, available on all major platforms. Liked this one? Don’t stop now. Here’s what we think you’ll love: https://www.wisenetix.com/blog?tag=the+oncology+insights+podcast What you will learn: (00:00) Highlight (00:45) Introduction (07:26) Theranostic imaging (17:00) Targeted radiation (22:57) PSMA development (25:57) PSMA imaging (27:26) Prostate therapy (30:26) Final Questions The Oncology Insights Podcast is trusted and supported by innovative companies like: - ZentrixOS (https://zentrixos.com/) - Zentrix Insights (https://zentrixinsights.com/) - Elevate (https://elevateagents.ai/) - WiseVAs (https://www.wisevas.io/) 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://oncologyinsightspodcast.com/ LinkedIn: https://www.linkedin.com/showcase/106601380/admin/dashboard/ Instagram: https://www.instagram.com/oncologyinsightspodcast/ Facebook: https://www.facebook.com/profile.php?id=61573169439464 TikTok: https://www.tiktok.com/@oncology.insights?lang=pt-BR

In this episode of The Oncology Insights Podcast, Dr. Maximilian Stahl, Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center, explains how acute myeloid leukemia care is becoming more precise. He discusses molecular testing, induction therapy selection, targeted agents, transplant decisions, APL advances, and early phase trials for high-risk AML. Listen now on all major platforms! "Molecular genetics now guide AML treatment selection, helping clinicians choose the best first therapy instead of simply starting the fastest regimen." Meet the guest: Dr. Maximilian Stahl https://www.linkedin.com/in/maximilianstahl-39b88a217 is Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center and Assistant Professor of Medicine at Yale School of Medicine. His work focuses on acute leukemia, early phase clinical trials, targeted therapy, measurable residual disease, and drug development for high-risk AML. Learn more from Dr. Maximilian Stahl on The Oncology Insights Podcast, available on all major platforms. Liked this one? Don’t stop now. Here’s what we think you’ll love: https://www.wisenetix.com/blog?tag=the+oncology+insights+podcast What you will learn: (00:00) Highlight (00:58) Introduction (05:59) AML testing (11:14) Transplant choices (17:00) Maintenance therapy (22:38) MRD monitoring (29:02) GVHD advances (39:14) Closing thoughts The Oncology Insights Podcast is trusted and supported by innovative companies like: - Elevate (https://elevateagents.ai/) - WiseVAs (https://www.wisevas.io/) - ZentrixOS (https://zentrixos.com/) - Zentrix Insights (https://zentrixinsights.com/) 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://oncologyinsightspodcast.com/ LinkedIn: https://www.linkedin.com/showcase/106601380/admin/dashboard/ Instagram: https://www.instagram.com/oncologyinsightspodcast/ Facebook: https://www.facebook.com/profile.php?id=61573169439464 TikTok: https://www.tiktok.com/@oncology.insights?lang=pt-BR

In this episode of The Oncology Insights Podcast, I speak with Dr. Xiuning Le, Associate Professor and Section Chief at The University of Texas MD Anderson Cancer Center, about the evolution of precision medicine in lung cancer. We discuss actionable mutations, targeted therapies, immunotherapy, early detection strategies, brain metastases, and emerging innovations shaping the future of oncology care. Listen now on all major platforms! "Targeted therapies are developed by understanding which oncogenic pathways drive tumor growth and identifying methods to overcome treatment resistance." Meet the guest: Dr. Xiuning Le https://www.linkedin.com/in/xiuning-le-a061065/ is a tenured Associate Professor and Section Chief in Thoracic and Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. Her research focuses on oncogene driven non small cell lung cancer, targeted therapies, brain metastases, and translational oncology. She has led clinical trials that contributed to new standards of care and FDA approvals. Listen to Dr. Xiuning Le on The Oncology Insights Podcast, available on all major platforms. Liked this one? Don’t stop now. Here’s what we think you’ll love: https://www.wisenetix.com/blog?tag=the+oncology+insights+podcast What you will learn: (00:00) Highlight (00:52) Introduction (05:38) Precision oncology (12:27) Actionable mutations (19:38) Immunotherapy biomarkers (25:14) Early detection (29:11) Brain metastases (32:20) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://oncologyinsightspodcast.com/ Instagram: https://www.instagram.com/oncologyinsightspodcast/ LinkedIn: https://www.linkedin.com/showcase/106601380/admin/dashboard/

In this episode of The Oncology Insights Podcast, I speak with Dr. Michael Postow, Chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, about how immunotherapy transformed melanoma care. Dr. Postow explores checkpoint inhibitors, combination strategies, biomarkers, and emerging approaches like cell therapies and personalized cancer vaccines. He explains patient outcomes, risks, and future innovations shaping oncology. Listen now on all major platforms! "Immune checkpoint inhibitors work by enhancing T cell activity, carefully adjusting immune response intensity to improve cancer control without triggering excessive autoimmune complications." Meet the guest: Dr. Michael Postow https://www.linkedin.com/in/michael-postow-0095461ab/ is Chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, specializing in immunotherapy and advanced melanoma research. His work focuses on checkpoint inhibitors, clinical trials, and innovative treatment strategies to improve patient outcomes. He continues to advance precision oncology and mentor future leaders in cancer care. Listen to Dr. Michael Postow on The Oncology Insights Podcast, available on all major platforms! Liked this one? Don’t stop now. Here’s what we think you’ll love: https://www.wisenetix.com/blog?tag=the+oncology+insights+podcast What you will learn: (00:00) Highlight (01:02) Introduction (03:59) Immunotherapy basics (05:08) Checkpoint combinations (07:39) Side effects risks (10:11) Biomarker challenges (16:04) Future therapies (29:34) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://oncologyinsightspodcast.com/ Instagram: https://www.instagram.com/oncologyinsightspodcast/ LinkedIn: https://www.linkedin.com/showcase/106601380/admin/dashboard/